UroGen Launches Initiative to Recognize Leaders in Urology

Got story updates? Submit your updates here. ›

UroGen Pharma, a biotech company focused on developing and commercializing innovative therapies for urological cancers, has launched a new initiative called the LG-UTUC Luminaries to recognize leaders in the field of upper tract urothelial carcinoma (UTUC). The program will honor individuals who have made significant contributions to advancing research, treatment, and patient care for this rare form of cancer.

Why it matters

UTUC is a challenging disease that often goes undiagnosed until it has progressed to an advanced stage. By honoring those who are driving progress in this area, UroGen hopes to raise awareness and inspire continued innovation to improve outcomes for UTUC patients.

The details

The LG-UTUC Luminaries initiative will accept nominations from the urology community to identify physicians, researchers, and other healthcare leaders who have demonstrated excellence in UTUC-related work. Award recipients will be recognized at an annual event and have the opportunity to share their insights and best practices with others in the field.

• The LG-UTUC Luminaries program was launched on April 8, 2026.

What’s next

UroGen will begin accepting nominations for the first LG-UTUC Luminaries awards in the coming months, with the inaugural ceremony planned for later this year.